| 1 |
Huynh TV, Davis AA, Ulrich JD, et al. Apolipoprotein E and Alzheimer's disease: the influence of apolipoprotein E on amyloid-beta and other amyloidogenic proteins [J]. J Lipid Res, 2017, 58(5): 824-836.
|
| 2 |
Roses AD. Apolipoprotein E affects the rate of Alzheimer disease expression: beta-amyloid burden is a secondary consequence dependent on APOE genotype and duration of disease [J]. J Neuropathol Exp Neurol, 1994, 53(5): 429-437.
|
| 3 |
Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium [J]. JAMA, 1997, 278(16): 1349-1356.
|
| 4 |
Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging [J]. Ann Neurol, 2010, 67(1): 122-131.
|
| 5 |
Sunderland T, Mirza N, Putnam KT, et al. Cerebrospinal fluid beta-amyloid1-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele [J]. Biol Psychiatry, 2004, 56(9): 670-676.
|
| 6 |
Farlow MR, He Y, Tekin S, et al. Impact of APOE in mild cognitive impairment [J]. Neurology, 2004, 63(10): 1898-1901.
|
| 7 |
Khan TA, Shah T, Prieto D, et al. Apolipoprotein E genotype, cardiovascular biomarkers and risk of stroke: systematic review and meta-analysis of 14, 015 stroke cases and pooled analysis of primary biomarker data from up to 60,883 individuals [J]. Int J Epidemiol, 2013, 42(2): 475-492.
|
| 8 |
Rojas S, Brugulat-Serrat A, Bargallo N, et al. Higher prevalence of cerebral white matter hyperintensities in homozygous APOE-varepsilon4 allele carriers aged 45-75: Results from the ALFA study [J]. J Cereb Blood Flow Metab, 2018, 38(2): 250-261.
|
| 9 |
Luo X, Jiaerken Y, Yu X, et al. Associations between APOE genotype and cerebral small-vessel disease: a longitudinal study [J]. Oncotarget, 2017, 8(27): 44477-44489.
|
| 10 |
Ji T, Zhao Y, Wang J, et al. Effect of Low-Dose Statins and Apolipoprotein E Genotype on Cerebral Small Vessel Disease in Older Hypertensive Patients: A Subgroup Analysis of a Randomized Clinical Trial [J]. J Am Med Dir Assoc, 2018, 19(11): 995-1002.e4.
|
| 11 |
Schilling S, DeStefano AL, Sachdev PS, et al. APOE genotype and MRI markers of cerebrovascular disease: systematic review and meta-analysis [J]. Neurology, 2013, 81(3): 292-300.
|
| 12 |
Gesierich B, Opherk C, Rosand J, et al. APOE varepsilon2 is associated with white matter hyperintensity volume in CADASIL [J]. J Cereb Blood Flow Metab, 2016, 36(1): 199-203.
|
| 13 |
Loehrer E, Ikram MA, Akoudad S, et al. Apolipoprotein E genotype influences spatial distribution of cerebral microbleeds [J]. Neurobiol Aging, 2014, 35(4): 899-905.
|
| 14 |
Groot C, Sudre CH, Barkhof F, et al. Clinical phenotype, atrophy, and small vessel disease in APOEepsilon2 carriers with Alzheimer disease [J]. Neurology, 2018, 91(20): e1851-e1859.
|
| 15 |
Maxwell SS, Jackson CA, Paternoster L, et al. Genetic associations with brain microbleeds: Systematic review and meta-analyses [J]. Neurology, 2011, 77(2): 158-167.
|
| 16 |
Paternoster L, Chen W, Sudlow CL. Genetic determinants of white matter hyperintensities on brain scans: a systematic assessment of 19 candidate gene polymorphisms in 46 studies in 19,000 subjects [J]. Stroke, 2009, 40(6): 2020-2026.
|
| 17 |
Hofer E, Cavalieri M, Bis JC, et al. White Matter Lesion Progression: Genome-Wide Search for Genetic Influences [J]. Stroke, 2015, 46(11): 3048-3057.
|
| 18 |
Manolio TA, Brooks LD, Collins FS. A HapMap harvest of insights into the genetics of common disease [J]. J Clin Invest, 2008, 118(5): 1590-1605.
|
| 19 |
Makela M, Kaivola K, Valori M, et al. Alzheimer risk loci and associated neuropathology in a population-based study (Vantaa 85＋) [J]. Neurol Genet, 2018, 4(1): e211.
|
| 20 |
Dierksen GA, Skehan ME, Khan MA, et al. Spatial relation between microbleeds and amyloid deposits in amyloid angiopathy [J]. Ann Neurol, 2010, 68(4): 545-548.
|
| 21 |
Pantoni L. Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges [J]. Lancet Neurol, 2010, 9(7): 689-701.
|
| 22 |
Hilal S, Ikram MA, Verbeek MM, et al. C-Reactive Protein, Plasma Amyloid-beta Levels, and Their Interaction With Magnetic Resonance Imaging Markers [J]. Stroke, 2018, 49(11): 2692-2698.
|
| 23 |
Lee S, Viqar F, Zimmerman ME, et al. White matter hyperintensities are a core feature of Alzheimer's disease: Evidence from the dominantly inherited Alzheimer network [J]. Ann Neurol, 2016, 79(6): 929-939.
|
| 24 |
Ma J, Yee A, Brewer HBJr , et al. Amyloid-associated proteins alpha 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer beta-protein into filaments [J]. Nature, 1994, 372(6501): 92-94.
|
| 25 |
Fagan AM, Watson M, Parsadanian M, et al. Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease [J]. Neurobiol Dis, 2002, 9(3): 305-318.
|
| 26 |
Lahoz C, Schaefer EJ, Cupples LA, et al. Apolipoprotein E genotype and cardiovascular disease in the Framingham Heart Stud y [J]. Atherosclerosis, 2001, 154(3): 529-537.
|
| 27 |
Greenberg SM, Vonsattel JP, Segal AZ, et al. Association of apolipoprotein E epsilon2 and vasculopathy in cerebral amyloid angiopathy [J]. Neurology, 1998, 50(4): 961-965.
|
| 28 |
Nicoll JA, Burnett C, Love S, et al. High frequency of apolipoprotein E epsilon 2 allele in hemorrhage due to cerebral amyloid angiopathy [J]. Ann Neurol, 1997, 41(6): 716-721.
|
| 29 |
McCarron MO, Nicoll JA, Stewart J, et al. The apolipoprotein E epsilon2 allele and the pathological features in cerebral amyloid angiopathy-related hemorrhage [J]. J Neuropathol Exp Neurol, 1999, 58(7): 711-718.
|
| 30 |
Koizumi K, Hattori Y, Ahn SJ, et al. Apoepsilon4 disrupts neurovascular regulation and undermines white matter integrity and cognitive function [J]. Nat Commun, 2018, 9(1): 3816.
|
| 31 |
Zlokovic BV. Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease [J]. JAMA Neurol, 2013, 70(4): 440-444.
|
| 32 |
Bezerra DC, Sharrett AR, Matsushita K, et al. Risk factors for lacune subtypes in the Atherosclerosis Risk in Communities (ARIC) Study [J]. Neurology, 2012, 78(2): 102-108.
|
| 33 |
Wardlaw JM, Allerhand M, Doubal FN, et al. Vascular risk factors, large-artery atheroma, and brain white matter hyperintensities [J]. Neurology, 2014, 82(15): 1331-1338.
|
| 34 |
Dickie DA, Ritchie SJ, Cox SR, et al. Vascular risk factors and progression of white matter hyperintensities in the Lothian Birth Cohort 1936 [J]. Neurobiol Aging, 2016, 42: 116-123.
|
| 35 |
Ke D, Zhou F, Liang H, et al. Hypertriglyceridemia Is Associated with Reduced Leukoaraiosis Severity in Patients with a Small Vessel Stroke [J]. Behav Neurol, 2018, 2018: 1361780.
|
| 36 |
Longstreth WT ArnoldJr, , Beauchamp NJ Jr , et al. Incidence, manifestations, and predictors of worsening white matter on serial cranial magnetic resonance imaging in the elderly: the Cardiovascular Health Study [J]. Stroke, 2005, 36(1): 56-61.
|
| 37 |
Schneider JA, Arvanitakis Z, Leurgans SE, et al. The neuropathology of probable Alzheimer disease and mild cognitive impairment [J]. Ann Neurol, 2009, 66(2): 200-208.
|
| 38 |
Schneider JA, Wilson RS, Bienias JL, et al. Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology [J]. Neurology, 2004, 62(7): 1148-1155.
|
| 39 |
Provenzano FA, Muraskin J, Tosto G, et al. White matter hyperintensities and cerebral amyloidosis: necessary and sufficient for clinical expression of Alzheimer disease? [J] JAMA Neurol, 2013, 70(4): 455-461.
|
| 40 |
Kim HJ, Im K, Kwon H, et al. Clinical effect of white matter network disruption related to amyloid and small vessel disease [J]. Neurology, 2015, 85(1): 63-70.
|
| 41 |
Greenberg SM, Briggs ME, Hyman BT, et al. Apolipoprotein E epsilon 4 is associated with the presence and earlier onset of hemorrhage in cerebral amyloid angiopathy [J]. Stroke, 1996, 27(8): 1333-1337.
|
| 42 |
O'Donnell HC, Rosand J, Knudsen KA, et al. Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage [J]. N Engl J Med, 2000, 342(4): 240-245.
|
| 43 |
Uddin MS, Kabir MT, Al Mamun A, et al. APOE and Alzheimer's Disease: Evidence Mounts that Targeting APOE4 may Combat Alzheimer's Pathogenesis [J]. Mol Neurobiol, 2018, 56(4): 2450-2465.
|